04 June 2024 : Laboratory Research
Molecular Prevalence and Geographical Variations of Carbapenem-Resistant Klebsiella pneumoniae ST15 Isolates in a Tertiary Hospital in Ningbo, China
Hui Gao1ACEFG*, Yanye Tu1BCDFG, Qingcao Li1BCF, Qiaoping Wu1ACEFDOI: 10.12659/MSM.943596
Med Sci Monit 2024; 30:e943596
Table 2 The antimicrobial resistance profile of 18 ST15 CRKP isolates [n(%)].
| Antimicrobials | ST15 CRKP (n=18) | |
|---|---|---|
| Susceptible | Resistant | |
| Amikacin | 11 (61.1) | 7 (38.9) |
| Ampicillin/sulbactam | 1 (5.6) | 17 (94.4) |
| Aztreonam | 4 (22.2) | 14 (77.8) |
| Ertapenem | 0 | 18 (100) |
| Nitrofurantoin | 1 (5.6) | 17 (94.4) |
| Trimethoprim/sulfamethoxazole | 14 (77.8) | 4 (22.2) |
| Ciprofloxacin | 2 (11.1) | 16 (88.9) |
| Piperacillin/tazobactam | 3 (20.0) | 15 (80.0) |
| Gentamicin | 3 (20.0) | 15 (80.0) |
| Cefepime | 3 (20.0) | 15 (80.0) |
| Cefoperazone/sulbactam | 16 (88.9) | 2 (11.1) |
| Ceftriaxone | 3 (20.0) | 15 (80.0) |
| Ceftazidime | 3 (20.0) | 15 (80.0) |
| Cefotetan | 4 (22.2) | 14 (77.8) |
| Cefotaxime | 3 (20.0) | 15 (80.0) |
| Tobramycin | 3 (20.0) | 15 (80.0) |
| Imipenem | 0 | 18 (100) |
| Levofloxacin | 2 (11.1) | 16 (88.9) |